Errol De Souza of Archemix Corporation;
Scott Gillis of NUCRYST Pharmaceuticals;
Judy Ozbun of the Massachusetts Biotechnology Educational Foundation;
Frank Thomas of Critical Therapeutics
Judy Ozbun , Errol De Souza, Scott H. Gillis, Scott Gillis, Thomas Duarte, Michael Rossman, Dan Wheeler, Jonathan Lakey, Keith Hoffman, Michael Andrews, Ronald Katz, James Gavin III, John Hagenbuch, Myron Wick III, Bertram Walls, John McLaughlin, Daniel W
Massachusetts Biotechnology Council Adds Four New Board Members
The Massachusetts Biotechnology Council has appointed four new members to its board of directors:
Twenty-three directors now sit on the board of the council, the nation’s oldest biotechnology trade association representing more than 500 organizations involved in life sciences and health care.
Four leaders join MBC Board (l to r):
New Director Named For Pennsylvania Governor's Action Team
Michael Rossman has been promoted to director of the Governor’s Action Team of economic development professionals reporting directly to Pennsylvania Gov. Edward Rendell. He previously served as chief operating officer for the team, which serves as a single point of contact for businesses considering locating or expanding in the Keystone State.
He succeeds Dan Wheeler, who resigned June 1 for undisclosed reasons. Rossman will guide a team of nearly two dozen economic development professionals situated in the state capital of , who resigned June 1 for undisclosed reasons. Rossman will guide a team of nearly two dozen economic development professionals situated in the state capital of Harrisburg and at offices statewide. The team works with companies and site consultants on projects deemed to possess significant investment, job creation or retention opportunities.
Rossman, who has worked for five Pennsylvania governors, has held numerous economic development positions with the state since July 1986, when he was a commerce development representative for the Department of Commerce, the forerunner of the current Department of Community and Economic Development.
He attended the Pennsylvania State University and the University of Missouri as a finance major and is certified as an economic development finance professional by the National Development Council. He is also member of the International Economic Development Council.
Biotech Development Veteran Joins Memphis Bioworks Foundation
Thomas Duarte has been named director of business development for the Memphis Bioworks Foundation following a nearly 28-year career in drug-related business development, the last three years as pharmaceutical life sciences specialist for FedEx.
Duarte will work on the development of UT-Baptist Research Park — primarily the Regional Biocontainment Laboratory, a research facility for the development of vaccines and diagnostics to protect against infectious diseases and bioterrorism. He will also work strategically with the Mid-South e-Health Alliance to strengthen the exchange of electronic patient information within the Memphis region.
At FedEx, Duarte was an industry marketing specialist focused on the diagnostics, pharmaceutical, biotech, and clinical trials segments.
The Memphis Bioworks Foundation is a not-for-profit organization formed in early 2001 to establish the Memphis region as an internationally recognized center for biomedical technology through education, research, job training, and commercialization.
MicroIslet Taps Diabetes Treatment Pioneer, Names Four to Board of Directors
Jonathan Lakey, a co-developer of the Edmonton Protocol treatment for type 1 diabetes, has been named chief scientific officer and a director of MicroIslet, a San Diego biotech company.
Lakey will lead MicroIslet's effort to accelerate the clinical introduction of cell based encapsulation therapy for persons with type 1 diabetes. He will work to set up and coordinate new trials outside of the United States. Lakey has been a member of the company's scientific advisory board since 2002.
Lakey was also one of four professionals elected to MicroIslet’s board of directors. The other three were Keith Hoffman, Michael Andrews, and Ronald Katz, who was elected the company’s new chairman. The four replace James Gavin III, John Hagenbuch, Myron Wick III, and Bertram Walls, who have resigned from the board.
Hoffman is chief operating officer of Thuris, a maker of medical devices and pharmaceuticals for central nervous system disorders, and has served as an intellectual property consultant to MicroIslet. He was also a founder or co-founder of: Thuris, OLAS Pharmaceuticals, Psych Pain Therapeutics, and Ansuma Biologics. Hoffman received his PhD from University of California Irvine for his work on the neuropharmacology of memory formation and Alzheimer's disease in the laboratory of Gary Lynch.
Andrews is the president of Worldwide LifeScience Technologies, which develops organizations in biotechnology and life sciences with a focus on Asia and the Pacific Rim. He holds patents in pharmaceutical processes and formulations, as well as memberships in the American Chemical Society and the International Society of Pharmaceutical Engineers.
Katz is a partner in the public accounting firm Weiser LLP and a MicroIslet investor, having participated in two prior private financings. He has a Bachelor of Science in Accounting and Management from New York University.
Seattle Genetics Names Two Board Members, New Chief Business Officer
John McLaughlin and Daniel Welch have joined the board of directors of Seattle Genetics in Bothell, Wash., while Eric Dobmeier has been promoted to the newly created position of chief business officer.
McLaughlin is CEO of Anesiva (formerly Corgentech), a developer of therapies to treat pain. Previously he was chairman and co-founder of Eyetech Pharmaceuticals, acquired in 2005 by OSI Pharmaceuticals, and president of Tularik, acquired in 2004 by Amgen. Earlier he held several senior management positions at Genentech. McLaughlin received a BA from the University of Notre Dame and a JD from the Catholic University of America.
Welch is CEO and president of InterMune, a biotech company focused on treatments for pulmonary and hepatic diseases. Previously he was chairman and CEO of Triangle Pharmaceuticals, acquired in 2003 by Gilead, and president of biopharmaceuticals at Elan. Earlier he held senior management roles at Sanofi-Synthelabo, now Sanofi-Aventis, and successor companies. Welch received a BA from the University of Miami and an MBA from the University of North Carolina.
Dobmeier was promoted from senior vice president, corporate development, where he oversaw Seattle Genetics' legal, corporate communications, strategic marketing and project management groups. During his five years with Seattle Genetics, he has led negotiation and completion of multiple corporate alliances. Dobmeier received an undergraduate degree from Princeton University and a law degree from Boalt Hall School of Law, University of California, Berkeley.